Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy
Alzheimer Disease
Epilepsy Intractable

Interventions

DRUG: NPT 2042 (bumetanide analog) or Matching Placebo

Sponsor

NeuroPro Therapeutics, Inc.